FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Davidson Matt | | | | | | 2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA] | | | | | | | | | | 5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director X 10% Owner | | | | |
|--|---|---------|--------|---|---------|---|--|--------|---|--|--------|---------------|--|--|---|--|--|--------------------------------|---|--|
| (Last) | (Fire | , | Middle | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/12/2019 | | | | | | | | | | Officer (give title elow) | | Other below) | (specify | |
| C/O VERRICA PHARMACEUTICALS INC. 10 NORTH HIGH STREET, SUITE 200 | | | | | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | |
| (Street) WEST CHESTE | R PA | . 1 | 9380 | 1 | | | | | | | | | | | | n filed by Mor | | • | | |
| (City) | (Sta | ate) (Z | Zip) | | | | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y | | | | | Year) i | Execution Date, | | | Transaction Disposed Of (D) Code (Instr. 5) | | | | s Acquired (A) or of (D) (Instr. 3, 4 and | | | Securities Beneficially Owned | | nership : Direct ect (I) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | Code | v | Amount | (A) (D) | or P | rice | Repo Trans | eported ansaction(s) str. 3 and 4) | | . 4) | (Instr. 4) | | | | |
| Common | 06/12/20 | 19 | | | | S ⁽¹⁾ | | 700 | I |) : | \$8.86 | 2, | 2,698,135 | | D | | | | | |
| Common Stock 06/13/2 | | | | |)19 | | | | s ⁽¹⁾ 1,431 | | I |) \$ | 10.03 | 3 ⁽³⁾ 2, | 2,696,704 | | D | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | rivative Conversion or Exercise (Month/Day/Year) str. 3) Price of Derivative Security Execution Date, if any (Month/Day/Year) | | | 5. Numbord of Derivativ Securitie Acquirec (A) or Disposec of (D) (Instr. 3, and 5) | | rative rities ired r osed) | 6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4) Amount or Numbor of Title Shares | | str. ount | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | | vnership rm: rect (D) Indirect (Instr. | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |

Explanation of Responses:

- 1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
- 2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$8.775 to \$8.905, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in
- 3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$10.00 to \$10.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact 06/14/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.